These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 24446037)

  • 21. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting.
    Lip GY; Huber K; Andreotti F; Arnesen H; Airaksinen KJ; Cuisset T; Kirchhof P; Marín F;
    Thromb Haemost; 2010 Jan; 103(1):13-28. PubMed ID: 20062939
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
    Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
    Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolving antithrombotic treatment strategies for acute ST-elevation myocardial infarction.
    Kandzari DE
    Rev Cardiovasc Med; 2006; 7 Suppl 4():S29-37. PubMed ID: 17224888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adenosine diphosphate receptor blockade in coronary intervention.
    Steinhubl SR
    J Invasive Cardiol; 2004 Jul; 16(7 Suppl):7S-10S. PubMed ID: 23573565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clopidogrel in acute coronary syndrome: implications of recent study findings.
    Duerschmied D; Bode C; Moser M
    Expert Rev Cardiovasc Ther; 2010 Sep; 8(9):1215-29. PubMed ID: 20828343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GP IIb-IIIa inhibitors administered upstream: evidence for improved outcomes with conventional and newer antithrombotic agents?
    Tricoci P; Newby LK
    Cardiol Rev; 2008; 16(2):89-94. PubMed ID: 18281911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bleeding and the use of antiplatelet agents in the management of acute coronary syndromes and atrial fibrillation.
    Vavalle JP; Rao SV
    Adv Cardiol; 2012; 47():125-40. PubMed ID: 22906908
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Appropriate anti-thrombotic/anti-thrombin therapy for thrombotic lesions.
    Iqbal Z; Rana G; Cohen M
    Curr Cardiol Rev; 2012 Aug; 8(3):181-91. PubMed ID: 22920489
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
    Capranzano P; Mehran R; Tamburino C; Stone GW; Dangas G
    Hosp Pract (1995); 2010 Nov; 38(4):38-43. PubMed ID: 21068525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Challenges in managing venous thromboembolism and acute coronary syndrome: case studies of the use of antithrombotic and antiplatelet therapies. Introduction.
    Haines ST
    Am J Health Syst Pharm; 2008 Aug; 65(15 Suppl 7):S3-4. PubMed ID: 18653823
    [No Abstract]   [Full Text] [Related]  

  • 31. Triple therapy: boon or bane for high-risk CV patients?
    Phillippe HM; Baty SR; Griffith CB
    J Fam Pract; 2011 Apr; 60(4):187-92. PubMed ID: 21472149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of dual antiplatelet therapy in high-risk patients with acute coronary syndromes.
    Guthrie RM
    J Fam Pract; 2015 Dec; 64(12 Suppl):. PubMed ID: 26845006
    [No Abstract]   [Full Text] [Related]  

  • 33. [Guidelines for percutaneous coronary interventions].
    Silber S; Albertsson P; Avilés FF; Camici PG; Colombo A; Hamm C; Jørgensen E; Marco J; Nordrehaug JE; Ruzyllo W; Urban P; Stone GW; Wijns W;
    Ital Heart J Suppl; 2005 Jul; 6(7):427-74. PubMed ID: 16082826
    [No Abstract]   [Full Text] [Related]  

  • 34. Antithrombotic and antiplatelet therapies in relation to risk stratification in patients with non-ST elevation acute coronary syndrome: insights from the Sino-Global Registry of Acute Coronary Events.
    Zhang LJ; Chen YD; Song XT; Zhao FH; Lü SZ
    Chin Med J (Engl); 2009 Mar; 122(5):502-8. PubMed ID: 19323898
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antithrombotic therapy in medically managed patients with non-ST-segment elevation acute coronary syndromes.
    Gurbel PA; Tantry US
    Heart; 2016 Jun; 102(11):882-92. PubMed ID: 26944654
    [No Abstract]   [Full Text] [Related]  

  • 36. Glycoprotein IIb/IIIa receptor inhibitors in 2008: do they still have a role?
    Mukherjee D; Roffi M
    J Interv Cardiol; 2008 Apr; 21(2):118-21. PubMed ID: 18384343
    [No Abstract]   [Full Text] [Related]  

  • 37. Novel platelet ADP P2Y12 inhibitors in the treatment of acute coronary syndrome.
    Tan GM; Lam YY; Yan BP
    Cardiovasc Ther; 2012 Aug; 30(4):e167-73. PubMed ID: 21883998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ticagrelor. Acute coronary syndromes: nothing new.
    Prescrire Int; 2011 Oct; 20(120):229-33. PubMed ID: 21970081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dual antiplatelet therapy plus oral anticoagulation: how does hemorrhagic risk impact stent selection?
    Giugliano GR; Lotfi AS
    JACC Cardiovasc Interv; 2008 Jun; 1(3):330; author reply 330-1. PubMed ID: 19463324
    [No Abstract]   [Full Text] [Related]  

  • 40. [Blockers of platelet glycoprotein IIb/IIIa-receptors in the treatment of patients with acute coronary syndrome and during transcutaneous coronary interventions].
    Fettser DV; Preobrazhenskiĭ DV; Batyraliev TA; Sidorenko BA; Aĭtach V
    Ter Arkh; 2009; 81(1):84-7. PubMed ID: 19253720
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.